Nutrabolt, the Austin-based company behind C4 energy drinks and the Bloom nutrition brand, has hired JPMorgan, Goldman Sachs, and Bank of America to lead a public offering that could raise up to $1 billion, according to four people familiar with the matter cited by Reuters. The company was last valued at $2.88 billion in 2022. Now it wants ordinary investors to decide whether that number still holds.

The IPO market has been in a strange place for the past few years: frozen for long stretches, then briefly thawed by a headline deal. SpaceX's debut earlier this month, the largest IPO on record, helped pull more companies off the sidelines. Consumer and retail brands have started filing again. Nutrabolt is reading that window and moving.

What Nutrabolt actually sells

The company was founded in 2002 and built its name on Cellucor protein powders before C4 became the energy drink you see in gas stations and gym bags. It also owns the XTEND recovery drink line. In 2024, it took a 20% stake in Bloom, a female-focused brand selling sparkling energy drinks, creatine gummies, hormone health capsules, and nutrition powders, then increased that stake the following year without disclosing the new percentage. In September 2025, Nutrabolt said it was on track to top $1 billion in annual revenue across its combined brands.

That revenue milestone matters because the last major outside investor, Keurig Dr Pepper, paid $863 million for a 30% stake in 2022, a price that worked out to roughly four times 2023 net sales. An IPO at a similar multiple would put the company in the $4 billion range. Whether public markets accept that math is the central question here.

The sector's record is not encouraging

Supplement and energy drink companies have had a rough time as public stocks. BellRing Brands, the owner of Premier Protein, went public in 2019 and its stock has since halved. Thorne, a vitamin maker, listed in 2021 and was taken private again by 2023. Thorne is currently exploring a sale, which is not typically what a healthy public story looks like.

Energy drink pure-plays have also been inconsistent. Celsius Holdings, which was briefly a Wall Street darling on the strength of its distribution deal with PepsiCo, has seen its stock fall 38% this year. Monster Beverage, the category's dominant player, is up 25% over the same period but trades as a mature business rather than a growth story.

Nutrabolt would be asking investors to pay a growth premium in a category where the growth story keeps disappointing after the IPO. C4 has real shelf presence and brand recognition, but so did Celsius before it ran into distribution headwinds that cut its growth rate sharply.

The distribution angle is worth watching closely. Keurig Dr Pepper holds a 30% stake in Nutrabolt and, more importantly, a long-term sales and distribution agreement. That relationship gives Nutrabolt nationwide reach it might not otherwise afford. It also means the company's distribution muscle is partly owned by a single outside partner, which is either a competitive advantage or a structural dependency, depending on how that partnership evolves after a public listing changes the ownership picture.

For consumers, Nutrabolt going public changes little in the short term. C4 will still be on the shelf, Bloom gummies will still be in the checkout aisle. What changes is who owns the upside and downside of the category's next move. If the energy drink boom continues, public shareholders capture it. If the market softens, as Celsius has already shown it can, those same shareholders absorb the loss.

The IPO timeline has not been disclosed. Given that the bank selection was only just reported, a listing is probably several months away at minimum.